This highly controlled diet intervention study sought to examine the impact of a DASH-style diet on changes in choline, choline metabolites, ceramides, and triglycerides in a cohort of obese adults aged 65–84 years. In response to the 12-week intervention, changes in plasma choline, DMG, total PC, total LPC, TMAO, total ceramide, and triglycerides resulted. Furthermore, the study diet influenced changes in individual LPC, sphingomyelin, and ceramide species.
4.1. In Response to the Dietary Choline and Betaine Provided by the DASH Diet, Plasma Choline Decreased and in Males Plasma Betaine Increased
The study diet provided an average of ~300 mg of dietary choline per day, which was delivered by food only, supplemental choline was not given. The amount of choline supplied by the study diet was below the adequate intake (AI) for adults which is 550 mg per day for males and 425 mg for females [
48]. Males in the 3 oz group received ~47% of the choline AI, whereas males in the 6 oz group received ~61% of the choline AI. Females in the 3 oz group received ~60% of the choline AI and females in the 6 oz group received ~79% of the choline AI. Data from the 2013–2014 National Health and Nutrition Examination Survey (NHANES) showed that the average daily choline intake in adults from food and beverages is 402 mg in males and 278 mg in females [
49]. Cross-sectional studies in adults from Canada and Tehran using food frequency questionnaires (FFQs) report an average dietary choline intake of 226 mg and 313 mg, respectively, with males consuming 372 mg and females 292 mg [
50,
51]. For the present study, the primary food sources of dietary choline were beef, eggs, and low-fat milk which are food items known to be high in choline [
45]. For this study, beef and low-fat milk were provided every day during the 12-week intervention. Given that the study diet was within the DASH guidelines for meat intake and provided choline below the AI, individuals adhering to the DASH diet may need to increase intakes of choline-rich foods or consider a choline supplement to meet the recommendation. However, choline from food is more bioavailable compared to supplements [
52].
In response to the study diet, plasma choline decreased by 9.6% from baseline to study end (
p = 0.012;
Table 4). Although there were no differences in plasma choline between the 3 oz and 6 oz beef intake groups at baseline or week 12 (
Table 2), males had higher plasma choline compared to females (
p = 0.042;
Table 3) at baseline. The higher plasma choline in males may be an indication of a higher dietary choline intake at baseline. Plasma choline concentrations reflect dietary choline intake and males consume more choline than females [
49,
50,
53,
54,
55]. In a 2-week randomized controlled crossover trial in individuals aged 17–70 years with a BMI range of 20–30 kg/m
2, participants consumed 97%, 47%, and 25% of the choline AI [
55]. In this study, plasma choline decreased from high choline intake to low choline intake. Similarly, the present study reports a decline in plasma choline over the 12-week intervention period in adults aged 65–84 years with a BMI of 32 kg/m
2. Interestingly, in response to the study diet, the change in plasma choline was in association with %body fat (
Table S1). Previously, we reported a decrease in %body fat and absolute fat mass in response to the diet intervention [
38]. Numerous human studies show that dietary choline and plasma choline are associated with reductions in body fat and improved body composition [
50,
56,
57,
58]. Indeed, the body composition profile of this cohort of obese older adults improved in response to the study diet [
35]. The association between choline and body fat in the present study may be due to the role of choline in hepatic fat removal and fatty acid oxidation. However, the amount of dietary choline for specific populations, such as obese older adults, that leads to an optimal reduction in body fat and improved body composition remains unknown and thus requires more investigation.
Estimated dietary betaine provided by the study diet had an average of 31.5 mg provided by food only, supplemental betaine was not given. The amount of betaine in the study diet was below dietary intakes reported by other studies. A 2017 systematic review and meta-analysis of six prospective cohort studies using FFQs reported a dietary betaine intake range of 41–478 mg in adults [
59]. Large cross-sectional studies report an average betaine intake of 78 mg and 110 mg with males consuming more betaine compared to females [
50,
51]. Betaine is obtained primarily from grains, cereal, beets, and spinach [
13,
60,
61]. In the present study, the main food sources of betaine were beef, spinach, and low-fat milk. Betaine functions primarily as an osmolyte and methyl-group donor with beneficial effects on alcohol-induced and metabolic-associated liver diseases, insulin resistance, cancer, and overall well-being [
62]. Betaine also preserves heart function, prevents pancreatic disease, and has a neuroprotective role. Given that there are no dietary recommendations for betaine and the amount of betaine required to improve health is undetermined, it is unknown whether amounts typically consumed by adults are optimal to achieve improved health and thus require further investigation.
In the present study, males had higher plasma betaine compared to females at week 12 (
p = 0.040;
Table 3). Gao et al. showed that compared to females, males had higher circulating betaine concentrations in association with lower body fat and higher lean body mass [
56]. In the present study, the change in plasma betaine was in association with %body fat (
Table S1). A large cross-sectional study of >3200 Canadian adults aged 42 years reported a dose-dependent decline in %body fat with increased betaine intake [
50]. However, dietary betaine assessed by FFQs showed that obese adults (BMI ≥ 30 kg/m
2) consumed less betaine compared to non-obese adults and thus had a lower reduction in body fat. A 2019 systematic review and meta-analysis of six randomized controlled trials reported the effectiveness of betaine supplements on reducing body fat and improving body composition in adults aged 18–60 years with betaine doses of 2.5–10 g per day [
63]. Betaine has also been shown to increase muscle mass, improve insulin signaling, and stimulate IGF-1 secretion [
64,
65,
66]. Indeed, we previously reported that in response to the study diet there was an increase in muscle strength with a reduction in muscle loss in association with an improved cardiometabolic profile [
38,
39,
40]. Furthermore, we showed a 10% increase in IGF-1 in association with decreased waist circumference and improved muscle function [
39]. Although these associations suggest that betaine may have a role in the interrelationships between body composition and cardiometabolic outcomes, more studies are needed in diverse populations to better understand the function of betaine in body composition outcomes and the dietary intake amount required to achieve beneficial health outcomes.
4.2. Plasma Dimethylglycine Decreased in Response to the DASH Diet, and Males Had Higher DMG Compared to Females
In the present study, the average estimated amount of dietary methionine was 1654 mg. In response to the study diet, plasma DMG decreased by 10% (
p = 0.042;
Table 4). Methionine showed no significant change. Differing plasma DMG and methionine concentrations are reported in response to various diet intervention studies. The inconsistent outcomes may be due to the variances in study design, target population, length of study, and choline and betaine dietary sources. For example, in a randomized, controlled crossover trial individuals aged 35–70 years with metabolic syndrome consumed 400 mg of choline per day through eggs or supplemental choline for 4 weeks [
67]. In response, DMG increased in both the egg and supplement groups. Methionine, however, did not change. In a 12-week parallel arm randomized placebo-controlled betaine supplement trial in individuals 21–70 years of age with obesity and prediabetes, plasma DMG increased by 16.5-fold and methionine by 1.5-fold in the supplement group compared to placebo [
68]. However, this study provided ~5000 mg of supplemental betaine which is 2.5 times the typical betaine intake. A 4-week parallel, placebo-controlled intervention provided wheat cereal and bread as betaine food sources to the habitual diets of adults aged 45–65 years with a BMI of ≥25 kg/m
2 [
69]. In response, both plasma DMG and methionine were higher in the cereal and bread group compared to the control. Given that DMG synthesis results from the remethylation of homocysteine to form methionine through betaine-homocysteine methyltransferase (BHMT), the decreased plasma DMG in the present study may reflect a reduction in BHMT activity due to the lower dietary choline and betaine provided by the study diet [
70,
71]. Furthermore, BHMT activity may be sensitive to food or supplemental sources of choline and/or betaine. More investigation is needed to delineate the dietary patterns that impact circulating DMG and methionine levels and the implications of plasma concentrations for human health.
At baseline, males had higher plasma DMG (
p = 0.001) and methionine (
p = 0.003) compared to females and at week 12 the higher plasma DMG (
p < 0.001) in males remained (
Table 3). A community-based study conducted by Van Parys et al. in western Norway found that both middle-aged and elderly males had higher plasma methionine compared to females with a choline intake of 260 mg per day assessed by FFQs [
72]. Unlike the present study, there were no changes in plasma DMG reported between males and females. Circulating concentrations of DMG and methionine may be associated with differential effects on health outcomes in older adults. For example, a 6-month nutritional supplement intervention, providing 55 mg of choline, in adults aged 65–98 years living in senior residences reported that increasing concentrations of DMG and methionine were associated with improved lipid metabolism and protection against cardiometabolic dysregulation [
73]. However, findings from a large population-based prospective study in adults 60+ years of age showed that plasma DMG is associated with an increased risk for colorectal cancer, whereas plasma methionine was associated with a reduced risk of colorectal cancer [
74]. Furthermore, outcomes from the Baltimore Longitudinal Study of Aging showed that older adults with low muscle quality presented with higher levels of plasma methionine [
75]. Although we previously reported reduced muscle loss and improved muscle strength and cardiometabolic health in response to the study diet [
35,
36], we observed no associations between plasma DMG or methionine and body composition or cardiometabolic outcomes. The mechanisms by which DMG and methionine play a causal or associative role in older adult health require further investigation. Furthermore, studies are needed to delineate the impact of diet on circulating concentrations of DMG and methionine.
4.3. Plasma Phosphatidylcholine Decreased in Response to the Dietary Phosphatidylcholine Provided by the DASH Diet
An estimated average of 81.5 mg of dietary phosphatidylcholine (PC) was provided by the study diet. The primary food sources of dietary PC were beef and eggs and in the present study beef was the main PC food item. Conflicting outcomes on metabolic health related to beef or dietary PC have been reported. A 28-day randomized crossover controlled feeding trial in overweight and obese adults aged 18–74 years with prediabetes and/or metabolic syndrome showed that beef within the Healthy US-Style Eating Pattern had no effects on cardiometabolic health [
76]. Similarly, a 2023 systematic review and meta-analysis of 21 randomized controlled trials reported that red meat consumption does not impact risk factors for T2DM [
77]. Conversely, a large observational study of >22,000 adults in the United States showed that a higher PC intake, assessed by FFQs, is associated with the risk of all-cause mortality and cardiovascular disease, specifically in those with diabetes [
78]. Outcomes of this study, however, were not interpreted within the context of diet quality or dietary pattern. In the present study, we investigated beef within the DASH diet in obese older adults and we observed improvements in cardiometabolic health [
39]. Health outcomes related to dietary PC and/or beef may need to be interpreted within the context of dietary patterns and more studies that determine whether causal relationships exist between dietary PC and risk of adverse health outcomes are needed.
In response to the 12-week diet intervention, plasma total PC decreased by 51% (
p < 0.001;
Table 4). Diet quality and/or dietary pattern may differentially influence plasma PC concentrations. For instance, a prospective cohort study in colorectal cancer patients showed that adherence to the World Cancer Research Fund dietary recommendations was associated with lower plasma PC, whereas higher intakes of a carnivore or Western dietary pattern were associated with higher plasma PC levels [
79]. The change in plasma PC in the present study was in association with skeletal muscle mass (
Table S1). In a 3-week low-calorie diet intervention study in obese adults, changes in specific PC species in muscle tissue were associated with improved insulin sensitivity [
80]. Moreover, plasma PC species are shown to be protective against insulin resistance and diabetes risk in older adults [
81]. Conversely, older adults with low muscle quality are reported to have lower plasma concentrations of PC [
75], potentially due to reduced mitochondrial function leading to decreased muscle function [
82]. Although we previously reported improved insulin sensitivity and muscle strength in response to the study diet [
38,
39], the impact of or implications for reduced plasma PC on metabolic health in older adults are unknown and thus require further investigation.
4.4. In Response to the DASH Diet Total Lysophosphatidylcholine Increased
The physiological functions and specific mechanisms by which lysophosphatidylcholine (LPC) acts have not been fully elucidated and human clinical lipidomic trials report conflicting outcomes [
83]. At baseline, participants randomized to the 3 oz beef intake group had higher plasma total LPC compared to participants randomized to the 6 oz beef intake group (
p = 0.05;
Table 2). Furthermore, in response to the diet, total LPC increased by 281% (
p < 0.001;
Table 4). This heightened increase in LPC may be due to the enhanced activity of phospholipase A, the enzyme responsible for converting PC to LPC [
84,
85]. Both overproduction and reduced concentrations of LPC are reported to be associated with unfavorable cardiometabolic outcomes, including diabetes, hypertension, and cardiovascular disease [
83,
86,
87]. Furthermore, decreased LPC has been observed with aging [
88]. In the present study, we report that the 281% increase in plasma total LPC is not in association with unfavorable cardiometabolic health outcomes. Although targeting LPC as a therapeutic option for treating cardiovascular disease has been suggested [
83], optimal plasma LPC levels that are associated with improved health have not been established and the mechanisms underlying LPC’s harmful, or beneficial effects are not well understood. Thus, more rigorous human lipidomic clinical trials delineating the role of LPC in health are required.
4.5. Trimethylamine N-Oxide Increased in Response to a Higher Beef Intake
Trimethylamine
N-oxide (TMAO) is a small organic compound derived from the oxidation of trimethylamine (TMA). Choline and L-carnitine serve as dietary precursors for TMAO synthesis and are both abundant in beef. The study diet provided an average of ~105 mg of dietary L-carnitine per day. In the present study, participants randomized to the 6 oz beef group had higher plasma TMAO at week 12 compared to those in the 3 oz beef group (
p = 0.033;
Table 2). Furthermore, in response to the study diet, TMAO increased by 26.5% (
p < 0.001;
Table 4). Plasma TMAO levels are influenced by the synthesis of TMA via gut microbes, which is likely a reflection of choline and L-carnitine supplied by the beef in the study diet. Circulating concentrations of TMAO have drawn attention as a potential mediator or biomarker of diseases such as obesity, cardiovascular disease, diabetes, kidney disease, and cancer [
88,
89,
90,
91,
92,
93,
94]. Various randomized controlled feeding trials and observational cross-sectional studies in which diet was assessed through FFQs or diet records report conflicting results on TMAO concentrations and associations with unfavorable disease outcomes in humans [
95,
96,
97,
98,
99,
100,
101,
102,
103,
104,
105]. The conflicts can likely be attributed to differences in study designs and characteristics and metabolic profiles of the study population. Although in the present study we observed that the change in plasma TMAO was in association with insulin and HOMA-IR (
Table S1), the cardiometabolic profile of this cohort of obese older adults improved in response to the study diet [
39]. The increase in plasma TMAO in the 6 oz beef group compared to the 3 oz group is likely due to the 6 oz group eating more beef. The question of whether TMAO is a cause or effect of impaired cardiometabolic health remains unknown [
106,
107] and until more is learned, changes in plasma TMAO should be interpreted within the context of diet, metabolic state, and/or changes within the gut microbiome.
4.6. Total Ceramide Decreased in Response to the DASH Diet
The bioactive sphingolipid ceramide receives attention due to its effects on insulin signaling and glucose utilization. Indeed, circulating ceramide concentrations are elevated in obese adults with T2DM and correlate with the severity of insulin resistance [
28,
30,
108]. Reductions in plasma ceramide have been demonstrated to coincide with reduced inflammation and improvements in insulin signaling [
30]. Numerous ceramide-reducing studies have been conducted using the potent drug myriocin which inhibits de novo synthesis of ceramide in the liver [
109]. Use of myriocin has been shown to resolve insulin resistance and atherosclerosis and prevent diabetes and heart failure [
109]. The ability, however, of diet to lower circulating ceramide is unexplored. In the present study, we observed a 22.1% reduction in total plasma ceramide from baseline to week 6 in response to the DASH diet used in this controlled feeding trial (
p < 0.001;
Table 4). Furthermore, we previously observed decreased inflammation and improved insulin signaling [
39]. Similarly, an 8-week feeding trial using the 2010 MyPlate Dietary Guidelines for Americans (DGA), counseling, and principles of behavior change demonstrated that circulating total ceramide decreased by week 5 in association with improved inflammatory status in adults aged 18–28 years with a BMI of 26 kg/m
2 [
32]. In this study, total ceramide decreased by 16% in the fruit–vegetable–low refined carbohydrate group and 48% in the fruit–vegetable–low fat group. Taken together, these outcomes suggest that the DASH and DGA dietary patterns have the potential to reduce circulating ceramide in association with an improved metabolic health profile in adults with overweight or obesity. Future diet interventions, however, need to assess the extent to which the ceramide-lowering ability of such diets prevents the development of metabolic disease in adults.
4.7. In Response to the DASH Diet Plasma Triglycerides Decreased and Males Had Higher Triglycerides Compared to Females
Studies show that the DASH diet significantly reduces plasma triglycerides in middle-aged overweight adults and individuals with metabolic syndrome [
110,
111]. However, a 2019 umbrella systematic review and meta-analysis found no significant impact of the DASH diet on triglyceride concentrations [
112]. In the present study, triglycerides decreased by 18% in response to the study diet (
p = 0.021;
Table 4). Several studies report associations between choline, betaine, and circulating triglycerides in middle-aged and older adults [
73,
99,
113]. The associations are likely due to the role that choline and betaine play in triglyceride levels. Choline is essential for the export of triglycerides into very-low-density lipoprotein molecules and betaine suppresses triglyceride synthesis and uptake [
114,
115,
116,
117,
118]. Conversely, high doses of betaine (4–6 g/day) and PC supplementation have been shown to increase triglycerides in humans [
119,
120]. In the present study, relationships between choline, betaine, and triglycerides were not observed, thus the decrease in triglycerides may be due to the impact of the DASH diet per se and not necessarily choline or betaine. Furthermore, it has been reported that calorie restriction and weight loss of at least 5% improve circulating triglycerides [
121,
122]. Indeed, we previously reported that the diet studied in this controlled feeding trial was restricted in calories throughout the 12-week intervention period and the participants lost 6% of total body weight by study end [
38]. Lastly, 6 of the 28 participants self-reported taking statin medications, which may also be a contributing factor to the reduced triglyceride levels observed in the present study.
At baseline, participants randomized to the 3 oz beef group had higher (
p = 0.023) plasma triglycerides compared to participants randomized to the 6 oz beef intake group (
Table 2). By week 12, participants consuming 6 oz of beef had higher (
p = 0.003) triglycerides compared to individuals consuming 3 oz of beef (
Table 2), which may be due to the 6 oz group eating more beef. Although both males and females had lower plasma triglycerides at study end, males had higher (
p = 0.003) triglycerides compared to females at week 12 (
Table 3). Previous reports of NHANES data show that males tend to have higher circulating triglycerides compared to females [
123,
124]. While triglyceride levels of ≥150 mg/dL are associated with negative cardiometabolic outcomes, results from the present study showed no such relationships, and thus the higher triglycerides are attributed to the consumption of beef within the study diet.
4.8. Lysophosphatidylcholine Species Increased in Association with Biomarkers of Inflammatory and Muscle Health
Lysophosphatidylcholines (LPCs) are bioactive lipids investigated in the development of atherosclerosis and inflammation [
22]. Conflicting outcomes on plasma concentrations of LPC species have been reported, resulting in difficulty interpreting results. For example, LPC species have been reported to be reduced and elevated in obesity and T2DM [
18,
19,
20,
21,
22]. However, LPC outcomes are generally not interpreted within the context of nutritional status or diet. Studies performed by Kus et al. and Barber et al. suggest that diet plays an important role in determining and altering the profile of plasma LPC species [
18,
125]. In the present study, plasma levels of 20 LPC species were measured and in response to the study diet all species increased (
p < 0.001;
Table 5). Of the LPC species measured, LPC 16:0 had the greatest response (
Table 5). LPC 16:0 is one of most abundant LPC species in plasma and has been shown to be related to metabolic health outcomes. In a case–control study investigating LPC species in adults with hypertriglyceridemia, LPC 16:0 was elevated and found to be a predictor of fasting triglyceride levels [
126]. Outcomes from a lifestyle intervention trial involving insulin-sensitive and insulin-resistant adults with non-alcoholic fatty liver (NAFL) showed that LPC 16:0 was higher in the insulin-sensitive group and may serve as a biomarker for insulin sensitivity in individuals with NAFL [
127]. In the present study, we observed that the change in LPC 16:0 and 20:4 was in association myostatin (
Table S1). Myostatin is a myokine produced in skeletal muscle where it inhibits muscle growth. We previously reported that in response to the study diet myostatin decreased by 17.6% in association with increased muscle mass and strength [
40]. Interestingly, low plasma LPC 18:2 has been shown to predict declines in gait speed in older adults [
128]. Gait speed is a measure of physical function and predicts disability and mortality in older adults. Considering that LPCs may serve as a protector for skeletal muscle against lipotoxicity [
129], further investigation is required to delineate the roles that individual LPC species may play in muscle health, particularly in older adults.
LPCs are widely considered to be potent pro-inflammatory lipids, however, recent discoveries suggest that LPCs may possess anti-inflammatory properties as well [
22]. In the present study, we observed that 10 of the 20 LPC species correlated with C-reactive protein (CRP) (
Table S1). CRP is a biomarker of inflammation and insulin resistance and is associated with coronary artery disease and total mortality [
130,
131,
132]. We previously reported that in response to the study diet CRP decreased by 11.3% [
39]. Previous studies show that LPC levels are inversely correlated with plasma CRP and LPC has the ability to bind CRP, resulting in delayed progression of atherosclerosis [
133,
134]. In the present study, we also observed that 10 of the 20 LPC species correlated with interleukin 8 (IL-8) (
Table S1). IL-8 is a chemokine associated with an increased risk for cardiovascular disease but also reported to have beneficial cardioprotective effects [
135,
136]. In response to the study diet, we previously reported a 38.8% increase in IL-8 in association with decreased total cholesterol, reduced LDL-C, and decreased glucose, indicating a cardioprotective role for IL-8 [
39]. The increased IL-8 we reported may be due to LPC’s ability to induce and promote IL-8 synthesis in endothelial cells [
137,
138]. While these associations collectively are suggestive of an anti-inflammatory role for LPCs in response to the DASH diet, this area remains largely unexplored. More studies are required to elucidate the relationship between diet and individual LPC species and delineate the impact of these relationships on cardiometabolic health in humans.
4.9. Sphingomyelin Species Respond Differentially in Association with Body Composition and Cardiometabolic Outcomes
Estimated dietary sphingomyelin provided by the study had an average of 17.5 mg. Dietary sphingomyelins are shown to be beneficial in lipid metabolism, cholesterol regulation, and in the prevention and treatment of metabolic diseases [
139,
140,
141]. In rodents, dietary sphingomyelin from eggs lowered fat mass and had the potential to prevent atherosclerosis [
142]. However, endogenous sphingomyelin species have been implicated in the etiology and pathogenesis of obesity, diabetes, atherosclerosis, and adipose tissue dysfunction [
143,
144,
145,
146,
147,
148]. In the present study, five sphingomyelin species were measured in plasma and of the five, sphingomyelin 16:0, 18:0, and 18:1 increased (all
p < 0.001) by 10.4%, 22.5%, and 24%, respectively (
Table 5). In contrast, we observed that sphingomyelin 24:0 significantly decreased by 10%. The change in sphingomyelin 18:0 and 18:1 was not in association with anthropometric or cardiometabolic outcomes. The relationships between circulating sphingomyelin species and health-related outcomes in humans differ and mechanisms that may explain relationships are not fully understood. For example, epidemiological and prospective cohort studies show that higher plasma sphingomyelin 16:0 is associated with incidence of heart failure, atrial fibrillation, and death, whereas higher plasma sphingomyelin 24:0 is related to lower risks of heart failure, atrial fibrillation, and death [
23,
24,
25]. In the present study, sphingomyelin 16:0 significantly increased by 10.4% (
Table 5) but was not in association with body composition or cardiometabolic outcomes. However, it is interesting to note that the 10.4% decrease in sphingomyelin 24:0 was associated with reduced total cholesterol, LDL-C, and glucose and increased IL-8 (
Table S1). Individual sphingomyelin species are involved in numerous biological actions and the changes in plasma concentrations and associations reported in this study and others may be due to collective biological activity across multiple pathways and cell types occurring simultaneously. Albeit, in the present study, the changes reported are in response to a diet intervention that contained dietary sphingomyelins, which is not considered in other studies. Given that dietary sphingomyelin is associated with improved metabolic health outcomes in humans and may have an impact on the profile of sphingomyelin species, future studies that investigate changes in sphingomyelin species in response to diet are needed to better elucidate the relationship between dietary sphingomyelin, endogenous sphingomyelin species, and metabolic health.
At baseline, females had higher plasma sphingomyelin compared to males (
p = 0.05;
Table 3). Although sphingomyelin levels remained higher in females at week 12, they were not statistically different from males (
p = 0.743;
Table 3). Higher plasma levels of sphingomyelins in females have been previously reported. A longitudinal cohort study of community-dwelling adults aged 55 years and older investigating cross-sectional relationships between sphingomyelins and lifestyle factors found that women had higher plasma sphingomyelin species compared to men [
149,
150]. Furthermore, women in the highest tertile for all sphingomyelin species (except SM 24:1) had a significantly reduced risk of Alzheimer’s disease (AD), whereas higher sphingomyelin levels among men were associated with an increased risk of AD [
150]. This suggests that differing plasma levels of sphingomyelin species may have differential effects on health in males and females, particularly those in the older adult population, which warrants further investigation.
4.10. In Response to the DASH Diet Ceramide Species Respond Differentially
The impact of diet on the profile of individual ceramide species is unexplored. In the present study, plasma concentrations of five ceramide species were measured. Although in response to the study diet total ceramide decreased (
Table 4), there was a differential impact of the diet on individual ceramide species. In response to the study diet, ceramide 22:0 and 24:0 decreased by 26.2% (
p < 0.001) and 11.2% (
p = 0.002), respectively (
Table 5). However, ceramide 24:1 increased by 37.5% (
p = 0.054;
Table 5). Mathews et al., however, reported that, in response to an 8-week diet intervention based upon the 2010 MyPlate DGA, ceramide 22:0, 24:0, and 24:1 decreased with an association between ceramide 22:0 and pro-inflammatory cytokines [
32]. In the present study, the change in ceramide 22:0 was in association with total cholesterol (
Table S1). The decreased ceramide 24:0 observed in the present study and by Mathews et al. may be viewed as favorable considering ceramide 24:0 is reported to be an antagonist of insulin action described as inhibiting glucose transport in skeletal muscle and negatively impacting insulin-stimulated glucose disposal [
151,
152]. However, high concentrations of ceramide 24:0 are associated with a reduced risk of atrial fibrillation and heart failure [
24,
25]. Although there is a consensus that ceramide may serve as a biomarker of metabolic disease in humans, the impact of diet on determining and altering the profile of ceramide species in various human populations and the relationship to human health warrants further investigation. Furthermore, clinical trials are needed to investigate the influence of diet on the divergent responses of ceramide species in human health.